Kidney Stone Treatment in India
Get Kidney Stone Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Kidney Stone Treatment in UAE
Kidney Stone Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Kidney stone treatment encompasses a spectrum of evidence-based interventions—from non-invasive extracorporeal shock wave lithotripsy (ESWL) and ureteroscopic laser lithotripsy to percutaneous nephrolithotomy (PCNL) for complex staghorn calculi—achieving stone-free rates of 85–98% depending on stone burden and technique. International patients choose India and the UAE through GAF Healthcare for access to high-volume urologists trained at globally accredited institutions, sub-24-hour diagnostic turnaround, and cost structures that are 40–70% below comparable care in Europe, North America, or Australia. GAF Healthcare provides end-to-end coordination—from pre-travel imaging review and specialist matching to post-procedure follow-up—so patients receive seamless, transparent care at JCI- and NABH-accredited hospitals in India or JCI- and DHA-licensed facilities across Dubai and Abu Dhabi.
Hospital Stay: 1–3 days (ESWL/URS); 3–5 days (PCNL or complex open/robotic cases) • Total Stay in Country (Fit-to-Fly): 1–2 weeks (minimally invasive procedures); 3–4 weeks (PCNL or staged bilateral procedures) • Success Rate: 85–98% stone-free rate (technique- and stone-burden-dependent)
What Is It?
Urolithiasis—the formation of calculi within the renal collecting system, ureter, bladder, or urethra—affects approximately 10–15% of the global population over a lifetime, with recurrence rates approaching 50% within 10 years if metabolic risk factors remain unaddressed. Stones form when urinary supersaturation of lithogenic salts (calcium oxalate, calcium phosphate, uric acid, struvite, or cystine) exceeds the inhibitory capacity of protective molecules such as citrate, Tamm-Horsfall protein, and osteopontin. Obstructive calculi trigger progressive hydronephrosis, renal parenchymal ischemia, and—in the setting of concurrent infection—urosepsis, making timely intervention clinically urgent.
The physiological sequelae of untreated upper-tract obstruction include activation of the renin-angiotensin-aldosterone axis, ipsilateral tubular atrophy, and contralateral compensatory hypertrophy. Serum creatinine and estimated glomerular filtration rate (eGFR) are monitored closely; obstruction lasting beyond four weeks is associated with a measurable and potentially irreversible decline in split renal function as quantified by MAG3 or DTPA nuclear renography. Concomitant urinary tract infection with urease-producing organisms (Proteus, Klebsiella) accelerates struvite stone growth into staghorn morphology and mandates urgent decompression via ureteral stenting or percutaneous nephrostomy before definitive stone clearance.
The contemporary standard of care follows the European Association of Urology (EAU) and American Urological Association (AUA) guidelines, which stratify management by stone size, location, composition (inferred by dual-energy CT Hounsfield units), and patient comorbidities. Stones ≤4 mm pass spontaneously in >80% of cases, often facilitated by alpha-1-adrenoceptor antagonists (tamsulosin, silodosin) under the medical expulsive therapy (MET) protocol. Stones 5–10 mm in the distal ureter are eligible for ESWL or ureteroscopy; stones >10 mm or those exhibiting high Hounsfield unit density (>1000 HU, typical of calcium oxalate monohydrate) are preferentially managed with ureteroscopic laser lithotripsy or PCNL. Metabolic workup—including 24-hour urine collection for oxalate, citrate, calcium, uric acid, and cystine—guides long-term preventive pharmacotherapy.
Candidates
• ELIGIBLE PATIENTS:
• Adults with symptomatic renal or ureteric calculi confirmed on non-contrast CT KUB (the gold-standard imaging modality with >95% sensitivity)
• Stones 5–20 mm suitable for ESWL: radiolucent or mildly radiopaque stones, Hounsfield units <900, no distal anatomical obstruction, stone-skin distance <10 cm
• Stones 10 mm–2 cm in the renal pelvis or upper ureter suitable for flexible ureteroscopy with holmium:YAG or thulium fiber laser (TFL) lithotripsy
• Stones >2 cm or complex/staghorn calculi requiring percutaneous nephrolithotomy (PCNL) or mini-PCNL (tract size 14–22 Fr)
• Patients with medically refractory renal colic unresponsive to NSAIDs (ketorolac, diclofenac) and alpha-blockers
• Patients with solitary kidney, bilateral obstruction, or obstructive uropathy with rising creatinine (urgent decompression indicated)
• Recurrent stone formers requiring combined stone clearance and metabolic risk factor evaluation
• Pediatric patients with congenital anomalies (horseshoe kidney, ureteropelvic junction obstruction) and concurrent calculi, managed at specialist centers
• REQUIRED PRE-PROCEDURE DIAGNOSTICS:
• Non-contrast CT KUB: stone size, location, Hounsfield units, skin-to-stone distance, hydronephrosis grade
• Ultrasound KUB: initial triage, radiation-free follow-up, detection of hydronephrosis
• Urine microscopy and culture (C&S): mandatory to exclude active infection before any instrumentation
• Full blood count (FBC), serum electrolytes, creatinine, eGFR, coagulation screen (PT/INR, aPTT)
• 24-hour urine metabolic panel (in recurrent stone formers): calcium, oxalate, citrate, uric acid, cystine, sodium, phosphate, urine volume
• Serum parathyroid hormone (PTH) and calcium if hypercalciuria or nephrocalcinosis is suspected
• MAG3/DTPA nuclear renography: split renal function assessment when significant hydronephrosis is present or before nephrectomy
• ECG and cardiopulmonary clearance for patients with significant comorbidities undergoing general anesthesia
• CONTRAINDICATIONS / RELATIVE CONTRAINDICATIONS:
• ESWL contraindicated in pregnancy, uncorrected coagulopathy (INR >1.5), active urinary tract infection (risk of sepsis), aortic or renal artery aneurysm, and morbid obesity limiting shock wave focusing
• High-density stones (>1200 HU, brushite/cystine composition) respond poorly to ESWL; ureteroscopy or PCNL preferred
• Uncorrected bleeding diathesis or therapeutic anticoagulation (warfarin, direct oral anticoagulants) must be bridged or reversed pre-operatively per institutional protocol
• Active systemic infection or urosepsis: requires urgent drainage (nephrostomy/stent) and IV antibiotics before definitive stone procedure
• Severe cardiopulmonary disease precluding general or regional anesthesia must be optimized before elective surgery
Procedure
CONSERVATIVE / MEDICAL MANAGEMENT: Small stones (≤4–5 mm) with no signs of obstruction, infection, or intractable pain are managed expectantly. Medical expulsive therapy (MET) using alpha-1-adrenoceptor antagonists—tamsulosin 0.4 mg/day or silodosin 8 mg/day—reduces time to spontaneous passage and analgesic requirement by relaxing ureteral smooth muscle. Alkalinization of urine with potassium citrate (pH target 6.0–6.5 for uric acid stones) can dissolve pure uric acid calculi over 4–8 weeks. Thiazide diuretics (hydrochlorothiazide, chlorthalidone) reduce hypercalciuric stone recurrence; allopurinol addresses hyperuricosuric calcium oxalate or uric acid stones; tiopronin or D-penicillamine is used for cystinuria.
EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY (ESWL): ESWL is a completely non-invasive outpatient procedure using focused acoustic shock waves—generated electrohydraulically, electromagnetically, or piezoelectrically—to fragment stones into passable particles. Modern C-arm fluoroscopy or ultrasound targeting allows precise localization. ESWL achieves stone-free rates of ~70–80% for renal pelvis stones ≤10 mm and ~60–70% for lower-pole stones. Sessions last 45–60 minutes; 1–3 sessions may be needed. A temporary ureteral stent (JJ/double-J stent) is often placed pre-ESWL for stones >10 mm to prevent steinstrasse (ureteral stone column). Retreatment is guided by KUB or ultrasound at 4–6 weeks.
URETEROSCOPY (URS) WITH LASER LITHOTRIPSY (FLEXIBLE & SEMI-RIGID): Ureteroscopy is the most versatile minimally invasive technique, performed under general or spinal anesthesia, with no external incision. Semi-rigid ureteroscopes address ureteral and lower-pole stones; single-use or reusable flexible digital ureteroscopes navigate the entire collecting system. The holmium:YAG laser (Ho:YAG, 2100 nm wavelength) is the historical gold standard, using both photothermal and photomechanical mechanisms to dust or fragment stones. The next-generation thulium fiber laser (TFL, 1940 nm) operates at higher peak absorption by water, enabling faster dusting at lower energy settings, reduced retropulsion, and superior stone-free rates in dense calculi. Stone fragments are retrieved with nitinol basket devices or left to pass as dust. A post-procedural JJ stent is placed for 1–2 weeks. Stone-free rates: 90–97% for ureteral stones, 85–93% for renal stones ≤2 cm.
PERCUTANEOUS NEPHROLITHOTOMY (PCNL) — STANDARD, MINI, ULTRA-MINI, MICRO: PCNL is the definitive treatment for large (>2 cm), staghorn, or ESWL/URS-refractory stones. Under fluoroscopic and/or ultrasound guidance, a percutaneous access tract is created through the flank directly into the renal collecting system. Standard PCNL uses a 24–30 Fr nephroscope; Mini-PCNL (14–22 Fr), Ultra-mini PCNL (11–13 Fr), and Micro-PCNL (4.85 Fr) progressively reduce blood loss, postoperative pain, and hospital stay while maintaining comparable stone-free rates (~85–95% for complete staghorn clearance after staged procedures). Intracorporeal lithotripsy is achieved with pneumatic, ultrasonic, electrohydraulic, or combination probes (e.g., Swiss LithoClast Master). Robotic-assisted PCNL is emerging at select high-volume centers, improving access precision in complex anatomy. A nephrostomy tube is typically placed at closure; tubeless or totally tubeless PCNL is practiced in selected cases.
RETROGRADE INTRARENAL SURGERY (RIRS): RIRS using flexible digital ureteroscopes and TFL laser is increasingly preferred over PCNL for stones 1.5–2.5 cm in suitable anatomy, offering comparable stone-free rates with fewer systemic complications, no percutaneous tract, and earlier discharge (day-case to overnight).
OPEN / LAPAROSCOPIC / ROBOTIC SURGERY: Pyelolithotomy, nephrolithotomy, or ureterolithotomy via open or laparoscopic approach is reserved for cases with concurrent anatomical pathology (e.g., ureteropelvic junction obstruction requiring simultaneous pyeloplasty), failed endoscopic approaches, or morbid anatomy precluding percutaneous access. Robot-assisted laparoscopic pyeloplasty with concomitant pyelolithotomy is performed at leading centers in India and the UAE using the da Vinci Xi system.
STENT MANAGEMENT: JJ ureteral stents placed for passive dilatation or post-procedure drainage are removed cystoscopically or via a pull-string under local anesthesia at 1–4 weeks. Stent-related symptoms (dysuria, frequency, hematuria, flank discomfort) are managed with alpha-blockers and anti-muscarinics.
Cost of Kidney Stone Treatment: India vs. UAE
The cost of kidney stone treatment varies significantly based on stone complexity, chosen procedure, hospital tier, and destination. India offers world-class urological care at 50–70% lower cost than the UAE, with no compromise on outcomes or technology—many Indian centers performing higher annual volumes of PCNL and laser ureteroscopy than equivalent Western institutions. The UAE, particularly Dubai and Abu Dhabi, offers premium hospital environments, multilingual care, and seamless accessibility for patients from the Middle East, East Africa, and Europe. GAF Healthcare provides transparent, all-inclusive cost packages with no hidden facility fees, so the estimates below reflect total procedural costs inclusive of surgeon fee, anesthesia, hospital stay, standard medications, and one follow-up imaging study.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $1,200 – $5,500 | ~55% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $3,000 – $12,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PRE-TRAVEL (2–4 WEEKS BEFORE DEPARTURE):
• Share existing imaging (CT KUB, ultrasound reports) and lab results with the GAF Healthcare clinical coordination team for remote specialist review.
• Receive a written treatment plan, itemized cost estimate, and hospital recommendation matched to stone complexity.
• Complete pre-anesthesia workup remotely where possible; any outstanding investigations are completed within 24 hours of arrival.
• Anticoagulants or antiplatelet agents are bridged or stopped per surgeon instruction (typically 5–7 days pre-operatively for warfarin; 48–72 hours for DOACs).
• Apply for e-Medical Visa (India) or confirm UAE entry requirements with GAF support; obtain travel insurance covering medical procedures.
ARRIVAL & ADMISSION (DAY 0–1):
• GAF Healthcare driver meets patient at airport; transfer to pre-arranged hospital-adjacent accommodation.
• Outpatient consultation with the urologist: clinical history, imaging review, stone risk scoring (e.g., CROES Nomogram for PCNL outcome prediction), and consent process.
• Final pre-operative investigations: urine C&S, FBC, coagulation, creatinine, ECG. Anesthesia review.
• Admission to hospital (typically the morning of the procedure).
PROCEDURE DAY:
• ESWL: Day-case procedure, 45–60 minutes, no anesthesia or mild sedation. Discharged same day with oral analgesia and alpha-blocker prescription.
• URS/RIRS with Laser Lithotripsy: General or spinal anesthesia, 60–90 minutes operative time. JJ stent placed. Foley catheter removed within 12–24 hours; discharge day 1–2 post-procedure.
• PCNL (standard or mini): General anesthesia, 90–150 minutes. Nephrostomy tube removed on post-operative day (POD) 2–3 once nephrostogram confirms clearance; discharge POD 3–5.
• Surgical specimen (fragmented stone) submitted for crystallographic analysis and microbiological culture.
POST-OPERATIVE IN-COUNTRY RECOVERY:
• POD 1–3: Oral fluids encouraged (target urine output ≥2 L/day), pain managed with oral NSAIDs/tramadol, antibiotics continued per culture sensitivity.
• POD 3–7 (ESWL/URS): Imaging (KUB X-ray or ultrasound) to confirm stone fragment passage or assess residual burden; JJ stent removal planned (if stented).
• POD 5–10 (PCNL): Nephrostomy removal after imaging clearance; wound review; creatinine check.
• JJ stent removal (if applicable): Cystoscopic or pull-string removal at 1–4 weeks; GAF coordinates outpatient appointment at treating hospital or, in select cases, with a urologist in the patient's home country.
• Metabolic evaluation: 24-hour urine collection initiated at week 2–4 to guide long-term preventive pharmacotherapy.
FIT-TO-FLY MILESTONES:
• ESWL: Fit to fly in 5–7 days (pending imaging showing no significant steinstrasse or ureteral obstruction).
• URS / RIRS: Fit to fly in 7–14 days (after stent removal and confirmation of uncomplicated recovery).
• PCNL (standard): Fit to fly in 2–3 weeks, once nephrostomy site is healed and imaging confirms adequate clearance.
• Complex staged bilateral PCNL: Fit to fly in 3–4 weeks.
FULL RECOVERY TIMELINE:
• Return to desk work: 1–2 weeks (ESWL/URS); 2–3 weeks (PCNL).
• Return to physical labor or heavy exercise: 4–6 weeks (PCNL).
• Long-term follow-up: KUB or low-dose CT at 3 and 12 months; 24-hour urine metabolic repeat at 6 months; recurrence prevention medications reviewed at each visit (coordinated remotely with GAF Healthcare).
Risks & Considerations
Kidney stone procedures are generally safe, but patients should be counseled on procedure-specific and patient-specific risks in accordance with informed consent standards. ESWL carries a small risk of renal hematoma (clinically significant in ~1%), cardiac arrhythmia (requiring ECG monitoring in patients with pacemakers or arrhythmia history), skin bruising, and transient hematuria. Steinstrasse—a column of fragments obstructing the ureter post-ESWL—occurs in ~4–7% of cases treated for larger stones and may require secondary ureteroscopy. Ureteroscopy and RIRS risks include ureteral perforation (<1%), ureteral avulsion (rare, <0.1%), post-operative urinary tract infection or pyelonephritis (2–5%), and stent-related lower urinary tract symptoms affecting quality of life in up to 40% of stented patients. PCNL carries higher procedural risk commensurate with its invasiveness: significant hemorrhage requiring transfusion (2–5%) or, rarely, angiographic embolization (<1%); pleural injury (hydrothorax in supra-costal access, ~5%); collecting system perforation; urosepsis (2–4%, highest risk in infected/struvite stone cases—mandating pre-operative urine sterilization); and adjacent organ injury (colon, spleen, liver; <0.5%). General anesthesia risks apply to all in-theater procedures and are stratified by ASA physical status classification. Patients with a solitary functioning kidney face additional risk of acute kidney injury peri-operatively and require nephrologist co-management. Long-term risks include ureteral stricture formation (1–2% post-URS) and stone recurrence (50% at 10 years without metabolic intervention). GAF Healthcare ensures pre-operative risk stratification, selects surgeons with complication rates benchmarked against national registry data, and maintains 24/7 clinical support throughout the patient's in-country stay.
Top Hospitals for Kidney Stone Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Manipal Hospitals
Bengaluru, India
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Top Doctors for Kidney Stone Treatment
Internationally trained specialists in Nephrology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Shri Ram Kabra
MBBS, MD, DNB
Nephrologist & Kidney Transplant Specialist
Marengo Asia Hospitals, Faridabad, Delhi NCR, India
22+ Yearsof experience
Dr. Shri Ram Kabra is the Director of the Department of Nephrology & Kidney Transplant Medicine at Marengo Asia Hospitals in Faridabad, Delhi NCR. With over 22 years of clinical experience, he has established himself as a leading nephrologist and kidney transplant specialist in the region. His medical qualifications include an MD from Safdurjang Hospital, New Delhi (2001) and a DNB from Pushpawati Singhania Research Institute, New Delhi (2008), providing… Read more
Dr. Suman Lata
MBBS, MD (Internal Medicine), DM (Nephrology), International Fellowship in Renal Transplant, FISN (Fellowship of Indian Society of Nephrology)
Nephrologist & Renal Transplant Physician
Manipal Hospital Dwarka, New Delhi, India
20+ Yearsof experience
Dr. Suman Lata is Head of Department and Consultant Nephrologist at Manipal Hospital Dwarka in New Delhi, specializing in comprehensive kidney disease management and renal transplantation. With over 20 years of clinical experience, she holds an MBBS, MD in Internal Medicine, and DM in Nephrology from Government Medical College, complemented by an international fellowship in renal transplantation from St George's Healthcare NHS Trust in London (2011). She… Read more
Dr. Venkat Sainaresh Vellanki
MSc — Solid Organ Transplantation, Accredited Fellowship — Kidney-Pancreas Transplantation, Division of Multiorgan Transplantation, Toronto General Hospital, University Health Network (UHN), University of Toronto, Fellow of the American Society of Nephrology (FASN), Designated Specialist Certification in Clinical Hypertension, Adult Nephrology Board Examination (RCPSCA), Accredited Clinical Fellowship — Adult Nephrology, University Health Network, University of Toronto, DM (Nephrology), Senior Residency in Nephrology, MD (Internal Medicine)
Nephrology & Kidney Transplant
Burjeel Medical City, Abu Dhabi, Abu Dhabi, UAE
15+ Yearsof experience
Dr. Venkat Sainaresh Vellanki is the Consultant and Head of Nephrology, and Director of Transplant Nephrology at Burjeel Medical City, Abu Dhabi — one of the region's most advanced quaternary care centres. He brings a rare combination of North American, British, and Indian training that spans clinical nephrology, interventional nephrology, and all modalities of kidney transplantation. After completing his MD in Internal Medicine at KMC Manipal University… Read more
Dr. Tanmay Pandya
DM Nephrology, MD General Medicine, MBBS
Nephrologist & Renal Transplant Specialist
Sarvodaya Hospital, Faridabad, India
26+ Yearsof experience
Dr. Tanmay Pandya is a highly accomplished nephrologist and renal transplant specialist with over 26 years of clinical excellence. Currently serving as HOD & Director of Nephrology & Renal Transplantation at Sarvodaya Hospital in Faridabad, he is recognised as one of the leading kidney disease specialists in the Delhi NCR region. A double gold medalist—earning distinction in both his MBBS and DM Nephrology programmes—Dr. Pandya combines exceptional… Read more
Dr. Salil Jain
MBBS, MD (Medicine), DNB (Nephrology), Clinical Fellowship in Nephrology & Kidney Transplant
Nephrologist & Renal Transplant Physician
Fortis Memorial Research Institute, Gurgaon, India
18+ Yearsof experience
Dr. Salil Jain is a renowned nephrologist with over 18 years of experience in the management of complex kidney disease and renal transplantation. He currently serves as Director & HOD — Nephrology & Renal Transplant at Fortis Memorial Research Institute, Gurgaon. His main clinical interests are acute kidney injury, kidney transplantation, and glomerulonephritis. Beyond clinical practice, Dr. Jain is actively involved in conducting awareness camps and… Read more
Frequently Asked Questions — Kidney Stone Treatment
The total cost of kidney stone treatment depends primarily on the procedure type and stone complexity. In India at JCI- or NABH-accredited hospitals, costs range from approximately USD 1,200 to USD 5,500, inclusive of surgeon and anesthesia fees, hospital stay, medications, and one post-operative imaging study. A straightforward ureteroscopic laser lithotripsy for a single ureteral stone typically costs USD 1,200–2,500, while a complex percutaneous nephrolithotomy (PCNL) for a staghorn calculus may reach USD 4,000–5,500. In the UAE (Dubai or Abu Dhabi) at JCI-accredited, DHA-licensed hospitals, equivalent procedures range from USD 3,000 to USD 12,000—reflecting premium facility infrastructure, luxury inpatient amenities, and higher operational costs. India is generally 50–70% more cost-effective for the same surgical outcome and equivalent or higher volume of procedural expertise. GAF Healthcare provides an itemized cost estimate before any commitment, with no hidden facility or administrative surcharges.
The fit-to-fly timeline depends on the specific procedure performed. For extracorporeal shock wave lithotripsy (ESWL), which is a non-invasive outpatient procedure, most patients can fly home within 5–7 days, provided follow-up imaging confirms no significant ureteral obstruction (steinstrasse) from stone fragments. After ureteroscopy or flexible ureteroscopic laser lithotripsy (RIRS) with JJ stent placement, patients are typically fit to fly in 7–14 days—following stent removal and clinical confirmation of uncomplicated recovery. After standard percutaneous nephrolithotomy (PCNL) for large or staghorn stones, the recommended in-country stay is 2–3 weeks to allow nephrostomy tube removal, wound healing, and imaging clearance. Complex or staged bilateral PCNL cases may require 3–4 weeks before safe long-haul travel. GAF Healthcare's clinical team issues a formal fit-to-fly certificate for travel insurance purposes, and coordinates stent removal with a urologist in your home country if early departure is medically justifiable.
Success rates for kidney stone treatment vary by procedure and stone characteristics, but contemporary minimally invasive techniques achieve excellent outcomes. ESWL achieves stone-free rates of 70–80% for renal pelvis stones ≤10 mm in a single session, with rates improving to ~85–90% after one to two repeat sessions for suitable stones. Ureteroscopic laser lithotripsy using holmium:YAG or next-generation thulium fiber laser (TFL) achieves stone-free rates of 90–97% for ureteral stones and 85–93% for renal stones up to 2 cm. Percutaneous nephrolithotomy (PCNL)—the treatment of choice for stones >2 cm and staghorn calculi—achieves stone-free rates of 85–95% for complete staghorn clearance after staged procedures, as confirmed by post-operative CT KUB. Residual fragment rates below 4 mm, sometimes called 'clinically insignificant residual fragments,' may still require long-term monitoring as they can serve as nidi for recurrence. Long-term recurrence-free survival is substantially improved with metabolic workup and targeted pharmacotherapy (potassium citrate, thiazides, allopurinol, or tiopronin as appropriate), which is initiated during the post-procedure stay and coordinated by the GAF Healthcare clinical team.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive non-medical coordination to ensure that every aspect of the patient's journey—before, during, and after the procedure—is managed with the same rigor applied to clinical care.
VISA & ENTRY DOCUMENTATION: For India: GAF Healthcare's visa team prepares and submits the e-Medical Visa application on the patient's behalf. The Indian e-Medical Visa is electronically issued within 24–72 hours for citizens of over 150 eligible countries, permits up to 60 days' stay with two re-entries, and allows one accompanying attendant on a concurrent e-Medical Attendant Visa. Patients requiring emergency intervention are fast-tracked with a hospital invitation letter. For UAE (Dubai / Abu Dhabi): Citizens of GCC countries and over 50 nationalities including the UK, EU, USA, Canada, and Australia receive visa-free entry or visa-on-arrival for up to 30–90 days. Patients from other nationalities receive GAF-facilitated UAE medical/tourist visa support. Dubai Health Authority (DHA) and Department of Health Abu Dhabi (DoH) licensed hospitals issue international patient welcome letters to expedite immigration formalities.
AIRPORT & GROUND TRANSFERS: Dedicated GAF Healthcare meet-and-greet at the arrival terminal with a signed patient name board. Private, air-conditioned, wheelchair-accessible vehicles are arranged for all airport-to-hospital and hospital-to-accommodation transfers. Inter-hospital transfers (e.g., for imaging at a partner diagnostic center) are included in the service package.
ACCOMMODATION: GAF pre-books serviced apartments or hotel rooms within 500m–1 km of the treating hospital for the patient's accompanying family member or caregiver. Options range from budget-friendly to four-star, with options for in-room meal delivery and housekeeping. All accommodation is vetted by GAF's on-ground team and priced transparently within the total package.
LANGUAGE & CULTURAL SUPPORT: Dedicated bilingual (Arabic, Russian, French, Swahili, Amharic, and other major languages) patient coordinators accompany patients to all consultations, explain consent documents, interpret discharge instructions, and serve as the primary point of contact for the treating medical team. This service is available seven days a week.
CLINICAL CONTINUITY: GAF Healthcare's medical team provides a structured discharge summary and digital records package (imaging on CD/DICOM, operative reports, histopathology/stone analysis, discharge prescriptions) formatted for direct use by the patient's home-country physician. Remote follow-up telemedicine consultations with the treating urologist are arranged at 4 weeks and 3 months post-procedure.
Patients Also Explore
Other treatments commonly sought by patients considering Kidney Stone Treatment.
Liver Transplant
Transplant
Lung Transplant
Transplant
TURP Surgery
Urology
Undescended Testicle Surgery
Urology